By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Sequenom has launched a public offering of 13 million shares of common stock priced at $4.15 per share.
The San Diego-based firm expects to raise gross proceeds of $54 million from the offering.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.